Literature DB >> 19251336

Higher dose requirements with insulin detemir in type 2 diabetes--three cases and a review of the literature.

Sanne G H A Swinnen1, J Hans DeVries.   

Abstract

We report on three type 2 diabetic patients whose daily basal insulin dose requirements were substantially reduced after switching from insulin detemir to insulin glargine. Meta-analysis of three randomised trials of basal insulin initiation confirmed this increased insulin detemir dose requirement in type 2 patients. Potential explanations are discussed.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19251336     DOI： 10.1016/j.diabres.2009.02.009

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN： 0168-8227            Impact factor:   5.602


  7 in total

1.  [Costs of diabetes care and treatment satisfaction in type 2 diabetes patients treated with a basal-bolus (ICT) insulin regimen in outpatient care: results of the LIVE-COM study].

Authors:  Ralph Achim Bierwirth; Thomas Kohlmann; Jörn Moock; Rolf Holle; Wolfgang Landgraf
Journal:  Med Klin (Munich)       Date:  2010-12-07

2.  A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs.

Authors:  Sanne G Swinnen; Marie-Paule Dain; Ronnie Aronson; Melanie Davies; Hertzel C Gerstein; Andreas F Pfeiffer; Frank J Snoek; J Hans Devries; Joost B Hoekstra; Frits Holleman
Journal:  Diabetes Care       Date:  2010-03-03       Impact factor: 17.152

3.  Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany.

Authors:  Stefan Pscherer; Eva Susanne Dietrich; Franz-Werner Dippel; Aileen Rae Neilson
Journal:  Ger Med Sci       Date:  2010-08-05

4.  No higher dose requirements with insulin detemir than glargine in type 2 diabetes: a crossover, double-blind, and randomized study using continuous glucose monitoring.

Authors:  Allen B King
Journal:  J Diabetes Sci Technol       Date:  2010-01-01

5.  Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus.

Authors:  Francesca Porcellati; Paola Lucidi; Paolo Rossetti; Paola Candeloro; Anna Marinelli Andreoli; Stefania Marzotti; Patrizia Cioli; Geremia B Bolli; Carmine G Fanelli
Journal:  Diabetes Care       Date:  2011-10-04       Impact factor: 19.112

6.  Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen.

Authors:  Jochen Seufert; Anja Borck; Peter Bramlage
Journal:  BMJ Open Diabetes Res Care       Date:  2019-10-01

Review 7.  Insulin therapy for type 2 diabetes.

Authors:  Sanne G Swinnen; Joost B Hoekstra; J Hans DeVries
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.